The scheme remains subject to the receipt of other statutory and regulatory approvals, including the approvals of the stock exchanges, SEBI, the National Company Law Tribunal, and the respective shareholders and creditors of GlaxoSmithKline Consumer Healthcare and the company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content